North Carolina 2025-2026 Regular Session

North Carolina House Bill H736

Introduced
4/2/25  

Caption

Pharmacists/Test and Treat

Impact

The implications of HB 736 on state laws are significant, as it amends existing definitions and practices of pharmacy in North Carolina. By defining pharmacists as healthcare providers who can perform testing, diagnosis, and treatment, the bill enhances their scope of practice and aligns reimbursement policies with those of other health professionals. Such changes could potentially reduce the burden on traditional healthcare settings like hospitals and clinics, improving patient outcomes by increasing the number of accessible testing locations.

Summary

House Bill 736 seeks to expand the role of pharmacists in North Carolina by allowing them to test and treat certain illnesses, including COVID-19 and influenza, with specific medications approved by the Board of Pharmacy. This bill aims to provide equitable reimbursement for healthcare services rendered by pharmacists, a move proponents argue will enhance patient access to care and meet the growing demand for healthcare services, especially in underserved areas. By enabling pharmacists to provide immediate testing and treatment, the bill is seen as a step towards integrating more healthcare services within community pharmacies.

Sentiment

The sentiment around HB 736 is largely positive among stakeholders advocating for increased healthcare access and reduced pressure on the healthcare system. Advocates, including many pharmacists and healthcare organizations, express confidence that this bill will empower pharmacists to play a crucial role in public health. However, some concerns have been raised regarding the preparedness and training of pharmacists to undertake such responsibilities, as well as the adequacy of reimbursement structures for these newly expanded services.

Contention

Notable points of contention include the potential for pharmacists to face challenges related to training and certification for performing tests, as well as the need for established protocols to ensure safe and effective patient care. Additionally, there may be apprehensions from traditional healthcare providers about the integration of pharmacists into roles that traditionally fall under their purview. The debate could highlight a broader dialogue on the shifting landscape of healthcare delivery and the role of various healthcare professionals in meeting public health needs.

Companion Bills

No companion bills found.

Similar Bills

AR SB104

To Amend The Arkansas Pharmacy Benefits Manager Licensure Act; To Protect Patients' Rights And Access To Medications; And To Declare An Emergency.

AR SB103

To Create The Pharmacy Nondiscrimination Act; To Require Pharmacy Benefits Managers To Accept Any Pharmacy Or Pharmacist Willing To Accept Relevant And Reasonable Terms Of Participation; And To Declare An Emergency.

RI S0685

Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.

RI H5854

Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.

NJ S3604

Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.

NJ A5212

Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.

NJ A3669

Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.

NC S335

Pharmacists/Test and Treat/Influenza & Strep